Expand all sections

Allergeenextract huisstofmijt

Acarizax

Extended indication House Dust Mite Allergy Trial In Children aged between 5 and 11 years.
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Allergeenextract huisstofmijt
Domain Chronic immune diseases
Reason of inclusion Indication extension
Main indication Other chronic immune diseases
Extended indication House Dust Mite Allergy Trial In Children aged between 5 and 11 years.
Proprietary name Acarizax
Manufacturer ALK-Abello
Route of administration Sublingual
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
ATMP No
Submission date 2025
Expected Registration 2026
Registration phase Clinical trials
Additional remarks Primary completion datum in april 2023.

Therapeutic value

Current treatment options Loratadine en cetirizine. Deze medicijnen kunnen zowel bij allergie voor huisdieren als bij allergie voor de huisstofmijt gebruikt worden.
Therapeutic value No estimate possible yet
Duration of treatment continuous
Frequency of administration 1 times a day
Dosage per administration 12 SQ-HDM
References NCT04145219 (MATIC)
Additional remarks SQ-HDM is de dosiseenheid voor Acarizax.

Expected patient volume per year

References GIP databank (1).
Additional remarks In 2023 waren er 6.627 gebruikers van Acarizax (1). Het is niet precies bekend hoeveel mensen met huisstofmijtallergie tussen de 5 en 11 jaar zijn.

Expected cost per patient per year

Cost > 1,206.30
References Medicijnkosten.nl (1).
Additional remarks Acarizax lyophilisaat voor sublinguaal gebruik 12 SQ-HDM: €3,60 (inclusief BTW) (1). Gebaseerd op dagelijks doorlopend gebruik kost een behandeling Acarizax €1.206,30 per patiënt per jaar (exclusief BTW).

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.